CMS Proposes Major RPM and RTM Billing Changes for 2027: What Urology Practices Must Know

QUICK ANSWER

• What is CMS proposing for RPM and RTM billing in 2027? As of September 2026, the CMS CY 2027 Physician Fee Schedule proposed rule (CMS-1848-P) includes four provisions that would fundamentally reshape urology billing for remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) under Medicare. If finalized, these CMS 2027 RPM changes would require an initiating visit before starting RPM or RTM, restrict billable monitoring time to employed clinical staff only, and reduce device supply reimbursement. The comment period closed September 14, 2026, and CMS is now reviewing submissions. The final rule is expected in November 2026.
• Outsourcing ban: CMS proposes that RPM and RTM treatment management time is payable only when performed by clinical staff directly employed by the billing practice, effectively ending third-party vendor billing models.
• Initiating visit required: Before RPM or RTM services begin, the billing practitioner must conduct a separately reportable face-to-face visit (in person or via telehealth) where remote monitoring is explicitly discussed and patient consent is obtained.
• Device revaluation: CMS proposes reducing practice expense values for RPM device supply and setup codes, which would lower per-patient monthly reimbursement even before the conversion factor cut takes effect.

What Changed in the 2027 Proposed Rule

On July 14, 2026, CMS released the CY 2027 Medicare Physician Fee Schedule proposed rule (CMS-1848-P), which includes the most significant restructuring of RPM and RTM billing requirements since Medicare began paying for these services. The rule followed an Office of Inspector General (OIG) report from September 2024, titled Additional Oversight of Remote Patient Monitoring in Medicare Is Needed (OEI-02-23-00260), which documented RPM enrollment growth from roughly 55,000 patients in 2019 to 570,000 in 2022.

CMS cited that growth as justification for tighter controls, even though the same OIG report found the vast majority of practices were billing appropriately. The proposed rule introduces four changes that affect RPM and RTM simultaneously. It is the same proposed rule that would delete G2211 and replace it with a modifier, so practices reviewing one change should review both together.

First, the employed-staff requirement: RPM and RTM treatment management codes (99457, 99458, 99470, and RTM equivalents) would only be payable when clinical staff performing the monitoring work are directly employed by the billing practice. Contracted third-party monitoring companies would no longer qualify. Second, the initiating visit: a separately reportable face-to-face encounter, either in person or via telehealth, must occur before RPM or RTM services begin. The visit must include explicit discussion of the monitoring plan and documented patient consent. Third, the established-patient requirement for RTM: RPM already required an established patient relationship. The 2027 rule would extend that same requirement to RTM. Fourth, device supply revaluation: CMS proposes reducing the practice expense relative value units (PE RVUs) for device setup and supply codes, which would lower the reimbursement attached to codes like 99453 and 99454.

CMS is also seeking public comment on whether to consolidate the current 17 RPM and RTM CPT codes into just four new HCPCS G-codes. That consolidation is a request for information at this stage, not a finalized proposal. The comment period closed September 14, 2026, and CMS is now reviewing all submissions. The final rule is expected in early November 2026, with changes taking effect January 1, 2027 if finalized as written.

Who Do the CMS 2027 RPM Changes Affect in Urology Billing?

Any urology practice that currently bills Medicare for RPM or RTM services, or plans to start a remote monitoring program, is directly affected. The proposed rule applies specifically to Medicare Part B claims, but commercial payers often follow CMS policy within one to two years, which means private-payer RPM programs could face similar requirements down the line.

Within urology, RPM has practical applications that go beyond the chronic disease management use cases most coverage focuses on. Post-operative monitoring after procedures like cystoscopy or lithotripsy, catheter output tracking after urologic surgery, blood pressure monitoring for patients on certain medications, and ongoing vitals tracking for patients managing chronic kidney conditions all fall under RPM-eligible workflows.

Practices that outsource their RPM monitoring to a third-party vendor face the most immediate disruption. Under the proposed rule, time logged by a contracted vendor’s clinical staff would not be billable. The practice could still purchase devices, software, and logistics support from a vendor, but the actual patient interaction and treatment management time must come from someone on the practice’s own payroll.

Solo practitioners and small urology groups that lack the staffing to dedicate a clinical team member to RPM management may find the economics of maintaining a monitoring program difficult under the new rules, especially with the simultaneous reduction in device supply reimbursement.

Why CMS Is Tightening RPM and RTM Requirements

CMS points to the OIG report as the primary driver. RPM enrollment grew roughly tenfold between 2019 and 2022, which drew scrutiny over whether the billing reflected genuine clinical oversight or whether some practices were collecting device data without meaningful patient engagement. The OIG recommended additional safeguards, and the 2027 proposed rule is CMS’s response.

The employed-staff provision targets a specific business model that grew during and after the COVID-19 public health emergency: third-party RPM vendors that supplied devices, collected data, and performed the treatment management calls on behalf of the billing practice. CMS’s concern is that this model can separate the clinical decision-making from the patient relationship, creating a gap where monitoring data is collected but not meaningfully integrated into the patient’s care plan.

The initiating visit requirement mirrors what CMS already requires for chronic care management (CCM). By requiring a face-to-face encounter before RPM or RTM begins, CMS aims to ensure the monitoring is clinically appropriate for the patient and that the patient understands what is being tracked and why. For urology practices, this is a documentation and workflow change. The visit can happen during a regular office encounter, as long as RPM or RTM is explicitly discussed and consent is documented. A routine follow-up where monitoring is never mentioned would not count as the initiating visit.

It is worth noting that this is a proposed rule, not a final rule. Based on industry pushback documented by the AAPC in August 2026 and legal analyses from firms tracking the proposed provisions, several elements, particularly the outsourcing ban and the G-code consolidation, may be narrowed or modified in the final rule. Practices should plan for the provisions as written while tracking the comment process.

What Does the RPM Outsourcing Ban Mean for Urology Practices?

In our experience matching providers with billing partners, one of the most common RPM setups we see in urology is a hybrid model: the practice prescribes the monitoring, a third-party vendor supplies the devices and handles the daily data collection, and the vendor’s clinical staff perform the 20-minute treatment management calls billed under CPT 99457. Under the proposed 2027 rule, that last step would no longer be billable if the staff performing it are employed by the vendor rather than the practice.

The financial impact depends on how the practice currently structures its RPM program. A mid-sized urology group with 100 RPM-enrolled Medicare patients billing 99454 (device supply) and 99457 (treatment management) monthly generates approximately $10,000 to $12,000 per month in recurring RPM revenue, or roughly $120,000 to $145,000 annually. If the treatment management component (99457 and 99458) becomes unbillable because the work is performed by a contractor, the practice loses the management revenue while still bearing the cost of the monitoring program.

The proposed rule does not ban vendors entirely. Practices can still purchase or lease devices, use vendor software platforms, and receive logistical support. The restriction applies specifically to who performs the billable clinical time. If the practice brings that function in-house by hiring or reassigning a clinical staff member, such as a medical assistant or nurse, to handle the RPM calls and documentation, the revenue remains intact.

The device supply revaluation stacks on top of the broader conversion factor reduction proposed for the same year, which our 2027 urology reimbursement guide breaks down in detail. Practices modeling next year’s RPM revenue need to account for both reductions, not just one.

Providers often come to us after a billing policy shift catches them mid-cycle, and what we hear most often about RPM is that practices launched programs without fully mapping the compliance requirements to their staffing model. If the outsourcing ban is finalized, practices that did not plan for in-house monitoring will need to restructure before January 1, 2027.

What Urology Practices Should Do Now Before the Final Rule

The comment period for the CY 2027 PFS proposed rule closed September 14, 2026. CMS is now reviewing submissions, and the final rule is expected in November 2026. While the window to influence the rule has passed, practices should use this period to prepare for the provisions as written. Here is what urology practices should act on now.

1. Audit your current RPM staffing model. Identify whether the clinical staff performing RPM treatment management calls (99457, 99458) are employed by the practice or by a contracted vendor. If vendor-employed, begin evaluating what it would take to bring that function in-house.
2. Model the revenue impact. Pull your last 12 months of RPM claims by CPT code. Calculate what you would lose if treatment management codes became unbillable under the current staffing arrangement. Compare that against the cost of hiring or reassigning a clinical staff member.
3. Review your initiating visit workflow. Map out how patients currently enter your RPM program. If there is no face-to-face encounter where RPM is explicitly discussed and consent documented, add that step to the enrollment process now. This change is low risk to implement early.
4. Check your RTM patient eligibility. If you bill RTM codes, confirm that every patient in the program has an established relationship with the billing practitioner. New patients would need an initial visit before RTM services begin.
5. Track the final rule and industry comment positions. The AUA and LUGPA both submitted formal comments during the open period. Monitor their published positions and any CMS responses. The final rule may narrow or modify key provisions, particularly the outsourcing ban and the G-code consolidation, so staying current on what is actually finalized will prevent premature restructuring.
6. Brief your billing team. Whether billing is handled in-house or by an outside billing company, the team processing RPM claims needs to know these changes are coming. Documentation requirements for the initiating visit, consent, and staff employment status should be built into the workflow before January 1, 2027, if the rule is finalized.

Common Misreadings of the RPM Proposed Rule

The most common misreading we see providers run into is treating this proposed rule as final. It is not. The comment period closed September 14, 2026, and CMS is now reviewing submissions. The final rule, expected in November, could narrow, delay, or withdraw any of the four provisions. The outsourcing ban and the G-code consolidation, in particular, have drawn significant industry opposition and may be modified. Plan for the provisions as written, but do not make irreversible staffing or program decisions until the final rule publishes.

A second misreading is assuming the outsourcing ban eliminates vendor relationships entirely. It does not. Practices can still contract with vendors for devices, software platforms, data infrastructure, and logistics. The restriction applies only to who performs the billable treatment management time. If the practice’s own employed clinical staff conduct the patient interaction and document the time, the vendor relationship can continue for everything else.

Third, some practices interpret the initiating visit as a brand-new standalone appointment. It is not. The initiating visit can be part of a regularly scheduled office encounter or a telehealth visit. The requirement is that RPM or RTM is explicitly discussed during that visit, the patient consents, and the visit is separately reportable. A routine visit where monitoring was never mentioned does not count, but a visit where it was discussed does, even if the visit had other clinical purposes.

Fourth, the proposed device supply revaluation is sometimes confused with the broader conversion factor reduction proposed for 2027. These are separate cuts that stack. The conversion factor drop affects all Medicare physician payments. The device supply PE revaluation specifically reduces the practice expense component of RPM device codes. A practice modeling its 2027 RPM revenue needs to account for both reductions, not just one.

Frequently Asked Questions

Next Steps

If your practice bills or plans to bill RPM under Medicare, the CY 2027 proposed rule requires immediate attention. Review the urology CPT code changes already in effect for 2026 to make sure your coding is current before layering on the 2027 changes.

Audit your RPM staffing model, model the revenue impact, and build the initiating visit into your enrollment workflow now. If billing complexity is exceeding what your in-house team can manage, connecting with a billing partner experienced in urology coding and compliance can close the gap before the January 1 effective date.

• Tracking the rest of the 2027 proposed rule? See our coverage of the G2211 deletion and modifier replacement and the 2027 conversion factor and reimbursement changes, both from the same CMS-1848-P rule.
• Managing prior authorization alongside RPM? The CMS electronic prior authorization rules for 2027 land on the same January 1 effective date.
• Ready to hand billing off? Get matched with a urology billing company that tracks CMS rule changes so your team does not have to.

CPT codes and descriptors are maintained by the American Medical Association and HCPCS Level II codes are maintained by CMS. Both are provided here for reference. The CY 2027 Medicare Physician Fee Schedule provisions described here are proposed and not final. Requirements, payment amounts, code structures, and effective dates may change in the final rule, so verify against the published final rule, your Medicare Administrative Contractor guidance, and individual payer policies before restructuring a monitoring program or submitting claims.